This trial is active, not recruiting.

Conditions chronic kidney diseases, kidney transplantation, dialysis, cognition disorders
Sponsor University of Minnesota - Clinical and Translational Science Institute
Start date April 2015
End date May 2018
Trial size 180 participants
Trial identifier NCT02421497, 1410M54981


Magnetic resonance imaging (MRI), as a non-invasive and non-contrast enhanced technique, has the potential to improve patient health care and management. The overall objective of proposed project is to:

1. develop, customize, and optimize anatomic and functional MRI methods,

2. explore the use of MRI methods to study CKD and evaluate post-transplant kidneys, and

3. investigate the potential of MRI in the diagnosis, prognosis, and monitoring of the progression of renal dysfunction.

In addition to direct studies of the kidney, brain MRI studies will also be performed to identify the cerebrovascular and cognitive effects of chronic renal function deficiency and medical treatment (e.g. hemodialysis and immunosuppression). The brain and kidneys have similar vascular bed, and both are susceptible to vascular injury, which provides the pathological basis for the widely recognized association of reduced renal function with prevalent cerebrovascular diseases (CVDs) and cognitive impairment (CI). The MRI methods in the brain will be applied to explore the origins for widely observed CVDs and prevalent cognitive impairment (CI) in kidney disease patients.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective

Primary Outcomes

Correspondence of MRI measures with clinical metrics (i.e. eGFR) and routinely assessed cognitive functions from CKD and ESRD patients.
time frame: up to three years
The potential of MRI methods in the evaluation of post-transplant kidneys.
time frame: Up to three years

Eligibility Criteria

Male or female participants from 18 years up to 70 years old.

For Specific Aim 1: MRI Technical Development Studies Inclusion Criteria: 1. Healthy Volunteer Exclusion Criteria: 1. Ferromagnetic implants 2. Any foreign metal objects in the body 3. History of shrapnel or shot gun injury 4. Cardiac pacemakers 5. Defibrillator 6. Neuronal stimulator 7. Magnetic aneurysm clip 8. Large tattoos on the abdomen or the brain and neck 9. Hip replacement 10. Too large to fit in the magnet (body mass index >= 40, approx.) 11. Severe claustrophobia 12. Women with pregnancy For Specific Aim 2: Pilot Studies with Patients Studies for CKD Inclusion 1. English- speaking as primary language. 2. Age 45 years and older 3. Able to complete an approximately 90 minute cognitive testing battery. 4. Able to sign the informed consent, or allow a caregiver, relative, surrogate, or witness to sign the informed consent if participant is unable to do so. 5. GFR < 90 ml/min/1.73m2 Exclusion 1. Acute psychiatric illness that would impede cognitive testing 2. Active chemical dependence, such as alcohol, narcotics or other drugs 3. Legally blind or unable to complete cognitive tests due to visual loss or deafness 4. Dialysis dependent or renal transplant recipient at time of screening or baseline 5. Chronic obstructive pulmonary disease 6. Severe CI unable to complete the Modified Mini-Mental State Examination [3MSE] Studies for Renal Transplantation Inclusion 1. Able to sign the informed consent, or allow a caregiver, relative, surrogate, or witness to sign the informed consent if participant is unable to do so. 2. Age 45 years and older Exclusion 1. Not on dialysis due to allograft failure 2. Chronic obstructive pulmonary disease

Additional Information

Official title MRI Technical Development and Applications in Kidney Disease
Principal investigator Xiufeng Li, Ph.D.
Description Specific Aims The overall objective is to develop and validate MRI methods for the evaluation and monitoring of renal status and associated cerebrovascular effects of renal dysfunction and treatment. The proposed project include two phases: 1) MRI technical development and validation with reproducibility studies; 2) clinical pilot studies with two patient populations (CKD patients and renal transplant recipients) to explore the potential of MRI in evaluating CKD, post-transplantation renal dysfunction and cerebrovascular pathophysiology associated with or induced by reduced kidney function and renal replacement treatment. The ultimate goal is to use MRI as a non-invasive and non-contrast enhanced tool to facilitate the diagnosis and prognosis of renal dysfunction and associated diseases, and to assess the efficacy of therapeutic interventions, and monitor disease progress across time. Specific Aim 1: Imaging technical development and protocol optimization for renal and cerebral MRI. The overall goal is to develop, customize and optimize new MRI methods to overcome challenges due to physiological motions and facilitate clinical research studies of renal and cerebral diseases, which will include but not are limited to the following aspects. Sub-Aim 1.1: Develop imaging methods to improve MRI quality and efficiency for renal disease studies. Sub-Aim 1.2: Optimize gas-challenge functional MRI protocols to study cerebral and renal vascular endothelial dysfunction. Sub-Aim 1.3: Evaluate the reproducibility of cerebral and renal MRI methods. Specific Aim 2: Perform pilot studies to evaluate the potential of MRI in CKD patients and renal transplant recipients. Sub-Aim 2.1: Evaluate the correspondence of MRI measures with clinical metrics (i.e. eGFR) and routinely assessed cognitive functions from CKD and ESRD patients. This will be accomplished by performing both cross-sectional and longitudinal studies, which will allow us to evaluate the diagnostic and prognostic potential of these non-invasive imaging methods. The investigators hypothesize that the measurements from cerebral and/or renal MRI can effectively reflect cerebral and/or renal (anatomic and physiological) changes induced by CKD or dialysis treatment. Sub-Aim 2.2: Investigate the potential of MRI methods in the evaluation of post-transplant kidneys. This will be accomplished by imaging transplant recipients in three distinct cohorts; those with good allograft function but coming in for routine protocol biopsy, with stable renal function, and with unstable renal function due to post-transplant complications. These patient populations will receive protocol biopsies (i.e. scheduled repeat biopsies) as standard of care; therefore pathologic results will be available for correlation with MRI measures. The investigators hypothesize that MRI methods can be a non-invasive surrogate marker of renal tissue properties and functional changes induced by renal post-transplant dysfunction (e.g. renal rejection) currently only obtained through biopsy.
Trial information was received from ClinicalTrials.gov and was last updated in June 2016.
Information provided to ClinicalTrials.gov by University of Minnesota - Clinical and Translational Science Institute.